



Crucell Announces STAR[®] Research License Agreement with Toyobo Gene Analysis Co. LTD.

Leiden, The Netherlands, 29 April 2008 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STAR[®] research license agreement with Toyobo Gene Analysis Co. LTD. Under the agreement, Toyobo Gene Analysis will evaluate Crucell's STAR[®] technology for generating cell lines for the production of recombinant proteins for third-party customers. Financial details of the agreement were not disclosed.

About STAR[®] Technology

STAR[®] technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell's PER.C6[®] human cell technology and the widely used Chinese hamster ovary (CHO) cell line. STAR[®] technology contains genetic elements, called STAR[®] elements that enable stable and high-yield gene expression important to recombinant antibody and protein production in mammalian cells. The technology has the potential to increase production yields, thereby reducing production costs.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biotechnology company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6[®] production technology. The Company licenses its PER.C6[®] technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Portugal, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.

About Toyobo Gene Analysis

TGAC (Osaka, Japan) established as a wholly-owned subsidiary of TOYOBO Co., Ltd., (Toyobo) in 1992 and since then it has contributed to "Toyobo's Biotech" in its role as one of domestic gene analyze company that can handle the human samples. In April of 2004, the biochemical research and contract manufacturing section was separated from Toyobo and joined TGAC. TGAC got possible to provide service to gene analysis, genetic recombination, cell culture and protein production for pre-clinical and clinical use. For more information see: <http://www.toyobo.co.jp/e/index.htm> Contact: info_tgac@toyobo.jp



Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in Europe (IFRS).

For further information please contact:

Media:

Barbara Mulder
Director Corporate Communications
Tel: +31-(0)71-519 7346
press@crucell.com

Investors/Analysts:

Oya Yavuz
Director Investor Relations
Tel: +31-(0)71-519 7064
ir@crucell.com